Spots Global Cancer Trial Database for Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy

Official Title: A Phase 2, Multicenter Study of Cabazitaxel Single Agent Administered as a 1-Hour Intravenous Infusion Every 3 Weeks to Evaluate the Safety, Tolerability and Anti-tumor Activity of Cabazitaxel in Patients With Advanced Gastric Adenocarcinoma Who Have Failed Prior Chemotherapy Regimens

Study ID: NCT01497964

Conditions

Gastric Cancer

Interventions

cabazitaxel XRP6258

Study Description

Brief Summary: Primary Objective: - To evaluate the anti-tumor activity of cabazitaxel by assessing objective tumor response rate (ORR) at the recommended dose (RD) when administered as a single agent every 3 weeks in patients with advanced gastric adenocarcinoma who have failed prior chemotherapy regimens Secondary Objectives: * To determine the RD of cabazitaxel when administered as a single agent every 3 weeks * To evaluate safety of cabazitaxel when administered as a single agent every 3 weeks * To estimate the overall survival (OS) and progression free survival (PFS) * To assess the pharmacokinetics (PK) profile of cabazitaxel in part 1

Detailed Description: Patients will be treated until disease progression, unacceptable toxicity, or patient's refusal of further study treatment. All patients will be followed during and after the study treatment until death or the end of study, whichever comes first.